<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006392</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068277</org_study_id>
    <secondary_id>S0000</secondary_id>
    <secondary_id>U10CA037429</secondary_id>
    <nct_id>NCT00006392</nct_id>
    <nct_alias>NCT00076128</nct_alias>
  </id_info>
  <brief_title>S0000 Selenium and Vitamin E in Preventing Prostate Cancer</brief_title>
  <acronym>SELECT</acronym>
  <official_title>Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer and Leukemia Group B</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the
      development of cancer. It is not yet known which regimen of selenium and/or vitamin E may be
      more effective in preventing prostate cancer.

      PURPOSE: Randomized phase III trial to determine the effectiveness of selenium and vitamin E,
      either alone or together, in preventing prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the effect of selenium and vitamin E administered alone vs in combination on the
           clinical incidence of prostate cancer.

        -  Compare the effect of these prevention regimens on the incidence of lung cancer,
           colorectal cancer, and all cancers combined in participants on this study.

        -  Compare the effect of these prevention regimens on prostate cancer-free survival, lung
           cancer-free survival, colorectal cancer-free survival, cancer-free survival, overall
           survival, and serious cardiovascular events in these participants.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2001</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Prostate Cancer</measure>
    <time_frame>Every six months for 7 to 12 years depending on when the participant was randomized.</time_frame>
    <description>Participants are seen at the study site every six month for an update of medical events. Prostate cancer diagnosis is based on participant report followed by the submission of a pathologic sample to central pathology review for confirmation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Lung Cancer</measure>
    <time_frame>Participants are assessed for medical every six months for 7 to 12 years depending on when he was randomized . Upon diagnosis of prostate cancer, updates are annual.</time_frame>
    <description>Participants are seen at the study site every six month for an update of medical events. Cancer diagnoses are based on participant report. Medical records for non-prostate cancers were collected but they were not pathologically confirmed. If the participant has been diagnosed with prostate cancer, study site visits are once a year. Follow-up was planned for seven to 12 years depending on when the participant was randomized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Colorectal Cancer</measure>
    <time_frame>Participants are assessed for medical every six months for 7 to 12 years depending on when he was randomized . Upon diagnosis of prostate cancer, updates are annual.</time_frame>
    <description>Participants are seen at the study site every six month for an update of medical events. Cancer diagnoses are based on participant report. Medical records for non-prostate cancers were collected but they were not pathologically confirmed. If the participant has been diagnosed with prostate cancer, study site visits are once a year. Follow-up was planned for seven to 12 years depending on when the participant was randomized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Diagnosis of Cancer</measure>
    <time_frame>Participants are assessed for medical every six months for 7 to 12 years depending on when he was randomized . Upon diagnosis of prostate cancer, updates are annual.</time_frame>
    <description>Participants are seen at the study site every six month for an update of medical events. Cancer diagnoses are based on participant report. Medical records for non-prostate cancers were collected but they were not pathologically confirmed. If the participant has been diagnosed with prostate cancer, study site visits are once a year. Follow-up was planned for seven to 12 years depending on when the participant was randomized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate Cancer Free Survival; Lung Cancer-free Survival, Colorectal Cancer-free Survival, Cancer-free Survival, Overall Survival</measure>
    <time_frame>Participants are assessed for medical every six months for 7 to 12 years depending on when he was randomized . Upon diagnosis of prostate cancer, updates are annual.</time_frame>
    <description>Participants are seen at the study site every six month for an update of medical events. If the participant has been diagnosed with prostate cancer, study site visits are once a year. Prostate cancer diagnosis is based on participant report followed by the submission of a pathologic sample to central pathology review for confirmation. Other cancer diagnoses are based on participant report. Medical records for non-prostate cancers were collected but they were not pathologically confirmed. Follow-up was planned for seven to 12 years depending on when the participant was randomized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Cardiovascular Events</measure>
    <time_frame>Participants are assessed for medical every six months for 7 to 12 years depending on when he was randomized . Upon diagnosis of prostate cancer, updates are annual.</time_frame>
    <description>Participants are seen at the study site every six month for an update of medical events. If the participant has been diagnosed with prostate cancer, study site visits are once a year. Cardiovascular events are based on self-report and are not confirmed. Follow-up was planned for seven to 12 years depending on when the participant was randomized.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">35533</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Vitamin E + selenium placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vitamin E and selenium placebo daily for 7-12 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selenium + vitamin E placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>selenium and vitamin E placebo daily for 7-12 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin E + selenium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vitamin E and selenium placebo daily for 7-12 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin E placebo + selenium placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>vitamine E placebo and selenium placebo daily for 7-12 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin E</intervention_name>
    <description>400 IU daily by mouth for 7-12 years</description>
    <arm_group_label>Vitamin E + selenium placebo</arm_group_label>
    <arm_group_label>Vitamin E + selenium</arm_group_label>
    <other_name>alpha tocopherol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selenium</intervention_name>
    <description>200 mcg daily for 7-12 years</description>
    <arm_group_label>Selenium + vitamin E placebo</arm_group_label>
    <arm_group_label>Vitamin E + selenium</arm_group_label>
    <other_name>L-selenomethionine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vitamin E placebo</intervention_name>
    <description>daily for 7-12 years</description>
    <arm_group_label>Selenium + vitamin E placebo</arm_group_label>
    <arm_group_label>Vitamin E placebo + selenium placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>selenium placebo</intervention_name>
    <description>daily for 7-12 years</description>
    <arm_group_label>Vitamin E + selenium placebo</arm_group_label>
    <arm_group_label>Vitamin E placebo + selenium placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Healthy male volunteers

          -  Digital rectal examination (DRE) deemed not suspicious for prostate cancer performed
             within 364 days prior to study entry

               -  Participants with a suspicious DRE are ineligible even if a recent or subsequent
                  biopsy is negative for cancer

          -  Total prostate-specific antigen ≤ 4.0 ng/mL within 364 days prior to study entry

          -  No prior prostate cancer or high-grade (grade 2-3) prostatic intraepithelial neoplasia

        PATIENT CHARACTERISTICS:

        Age:

          -  See Disease Characteristics

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        Cardiovascular:

          -  Systolic blood pressure &lt; 160 mm Hg

          -  Diastolic blood pressure &lt; 90 mm Hg

          -  No history of hemorrhagic stroke

        Other:

          -  No malignancies within the past 5 years except basal cell or squamous cell skin cancer

          -  No uncontrolled medical illness

          -  No retinitis pigmentosa

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified

        Other

          -  At least 7 years since prior randomization to SWOG-9217, with completion of
             end-of-study biopsy requirement

          -  No additional concurrent selenium or vitamin E (contained in individual supplements,
             antioxidant mix, or multivitamin)

          -  Concurrent multivitamins allowed (supplied on study)

          -  No concurrent anticoagulation therapy (e.g., warfarin)

          -  Concurrent prophylactic aspirin (average daily dose no greater than 175 mg/day)
             allowed

               -  Concurrent daily aspirin dose ≤ 81 mg for participants receiving clopidogrel

          -  Concurrent anti-hypertension medication allowed

          -  No concurrent participation in another study involving a medical, surgical,
             nutritional, or life-style intervention (unless no longer receiving the intervention
             and are in the follow-up phase only)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Klein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philip J. Walther, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurence H. Klotz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Toronto Sunnybrook Regional Cancer Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Scott M. Lippman, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>MD Anderson</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ian M. Thompson, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J. Michael Gaziano, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>MAVERIC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel D Karp, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Beth Israel Deaconess</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fadlo R. Khuri, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>MD Anderson</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael M Lieber, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Center for Hematology/Oncology</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardinal Bernardin Cancer Center at Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Cancer Research for the Ozarks</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Regional Health Center</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital Cancer Treatment Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bethesda North Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tod Children's Hospital</name>
      <address>
        <city>Youngstown</city>
        <state>Ohio</state>
        <zip>44501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LaFortune Cancer Center at St. John Medical Center</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Group - Scenery Park</name>
      <address>
        <city>State College</city>
        <state>Pennsylvania</state>
        <zip>16801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center</name>
      <address>
        <city>Wilkes-Barre</city>
        <state>Pennsylvania</state>
        <zip>18711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.T. Cancer Institute at University of Tennessee Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920-6999</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Peru</country>
    <country>Puerto Rico</country>
  </removed_countries>
  <link>
    <url>http://www.crab.org/select/</url>
    <description>Web site for additional information</description>
  </link>
  <reference>
    <citation>Hoque A, Albanes D, Lippman SM, Spitz MR, Taylor PR, Klein EA, Thompson IM, Goodman P, Stanford JL, Crowley JJ, Coltman CA, Santella RM. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes Control. 2001 Sep;12(7):627-33.</citation>
    <PMID>11552710</PMID>
  </reference>
  <reference>
    <citation>El-Bayoumy K. The negative results of the SELECT study do not necessarily discredit the selenium-cancer prevention hypothesis. Nutr Cancer. 2009;61(3):285-6. doi: 10.1080/01635580902892829.</citation>
    <PMID>19373601</PMID>
  </reference>
  <reference>
    <citation>Cook ED, Moody-Thomas S, Anderson KB, Campbell R, Hamilton SJ, Harrington JM, Lippman SM, Minasian LM, Paskett ED, Craine S, Arnold KB, Probstfield JL. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clin Trials. 2005;2(5):436-42.</citation>
    <PMID>16315648</PMID>
  </reference>
  <reference>
    <citation>Kristal AR, King IB, Albanes D, Pollak MN, Stanzyk FZ, Santella RM, Hoque A. Centralized blood processing for the selenium and vitamin E cancer prevention trial: effects of delayed processing on carotenoids, tocopherols, insulin-like growth factor-I, insulin-like growth factor binding protein 3, steroid hormones, and lymphocyte viability. Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):727-30.</citation>
    <PMID>15767358</PMID>
  </reference>
  <reference>
    <citation>Lippman SM, Goodman PJ, Klein EA, Parnes HL, Thompson IM Jr, Kristal AR, Santella RM, Probstfield JL, Moinpour CM, Albanes D, Taylor PR, Minasian LM, Hoque A, Thomas SM, Crowley JJ, Gaziano JM, Stanford JL, Cook ED, Fleshner NE, Lieber MM, Walther PJ, Khuri FR, Karp DD, Schwartz GG, Ford LG, Coltman CA Jr. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst. 2005 Jan 19;97(2):94-102.</citation>
    <PMID>15657339</PMID>
  </reference>
  <results_reference>
    <citation>Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009 Jan 7;301(1):39-51. doi: 10.1001/jama.2008.864. Epub 2008 Dec 9.</citation>
    <PMID>19066370</PMID>
  </results_reference>
  <results_reference>
    <citation>Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011 Oct 12;306(14):1549-56. doi: 10.1001/jama.2011.1437.</citation>
    <PMID>21990298</PMID>
  </results_reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <results_first_submitted>June 12, 2012</results_first_submitted>
  <results_first_submitted_qc>October 5, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 6, 2012</results_first_posted>
  <last_update_submitted>October 23, 2015</last_update_submitted>
  <last_update_submitted_qc>October 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
    <mesh_term>Selenium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Men were randomized at 427 study sites in the US, Puerto Rico and Canada between August 22, 2001 and June 24, 2004.</recruitment_details>
      <pre_assignment_details>Prior to randomization, there was a three month formal pre-randomization period with no placebo run-in capsules to give potential participants to decide if they would agree to stop disallowed over-the-counter supplements of selenium or vitamin E. By returning for randomization, they exhibited their willingness to adhere to the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vitamin E</title>
          <description>Vitamin E + matching placebo for selenium</description>
        </group>
        <group group_id="P2">
          <title>Selenium</title>
          <description>Selenium + matching placebo for vitamin E</description>
        </group>
        <group group_id="P3">
          <title>Combination</title>
          <description>Vitamin E + selenium</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Matching placebo for vitamin E + matching placebo for selenium</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8904"/>
                <participants group_id="P2" count="8910"/>
                <participants group_id="P3" count="8863"/>
                <participants group_id="P4" count="8856"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8737"/>
                <participants group_id="P2" count="8752"/>
                <participants group_id="P3" count="8703"/>
                <participants group_id="P4" count="8696"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="167"/>
                <participants group_id="P2" count="158"/>
                <participants group_id="P3" count="160"/>
                <participants group_id="P4" count="160"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor data/ppt mgmt, regulatory problems</title>
              <participants_list>
                <participants group_id="P1" count="156"/>
                <participants group_id="P2" count="155"/>
                <participants group_id="P3" count="155"/>
                <participants group_id="P4" count="155"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vitamin E</title>
          <description>Vitamin E + matching placebo for selenium</description>
        </group>
        <group group_id="B2">
          <title>Selenium</title>
          <description>Selenium + matching placebo for vitamin E</description>
        </group>
        <group group_id="B3">
          <title>Combination</title>
          <description>Vitamin E + selenium</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Matching placebo for vitamin E + matching placebo for selenium</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8737"/>
            <count group_id="B2" value="8752"/>
            <count group_id="B3" value="8703"/>
            <count group_id="B4" value="8696"/>
            <count group_id="B5" value="34888"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.4" lower_limit="58.1" upper_limit="67.8"/>
                    <measurement group_id="B2" value="62.6" lower_limit="58.1" upper_limit="67.8"/>
                    <measurement group_id="B3" value="62.3" lower_limit="58.0" upper_limit="67.8"/>
                    <measurement group_id="B4" value="62.6" lower_limit="58.2" upper_limit="68.0"/>
                    <measurement group_id="B5" value="62.3" lower_limit="58.1" upper_limit="67.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8737"/>
                    <measurement group_id="B2" value="8752"/>
                    <measurement group_id="B3" value="8703"/>
                    <measurement group_id="B4" value="8696"/>
                    <measurement group_id="B5" value="34888"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6890"/>
                    <measurement group_id="B2" value="6942"/>
                    <measurement group_id="B3" value="6874"/>
                    <measurement group_id="B4" value="6863"/>
                    <measurement group_id="B5" value="27569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1107"/>
                    <measurement group_id="B2" value="1053"/>
                    <measurement group_id="B3" value="1076"/>
                    <measurement group_id="B4" value="1078"/>
                    <measurement group_id="B5" value="4314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic (non-African American)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="477"/>
                    <measurement group_id="B2" value="481"/>
                    <measurement group_id="B3" value="484"/>
                    <measurement group_id="B4" value="492"/>
                    <measurement group_id="B5" value="1934"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic (African American)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="95"/>
                    <measurement group_id="B4" value="76"/>
                    <measurement group_id="B5" value="360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="190"/>
                    <measurement group_id="B3" value="174"/>
                    <measurement group_id="B4" value="187"/>
                    <measurement group_id="B5" value="711"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7463"/>
                    <measurement group_id="B2" value="7471"/>
                    <measurement group_id="B3" value="7427"/>
                    <measurement group_id="B4" value="7428"/>
                    <measurement group_id="B5" value="29789"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="909"/>
                    <measurement group_id="B2" value="915"/>
                    <measurement group_id="B3" value="911"/>
                    <measurement group_id="B4" value="904"/>
                    <measurement group_id="B5" value="3639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="365"/>
                    <measurement group_id="B2" value="366"/>
                    <measurement group_id="B3" value="365"/>
                    <measurement group_id="B4" value="364"/>
                    <measurement group_id="B5" value="1460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age (categorical)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>50 - 54 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="402"/>
                    <measurement group_id="B2" value="337"/>
                    <measurement group_id="B3" value="385"/>
                    <measurement group_id="B4" value="355"/>
                    <measurement group_id="B5" value="1479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>55 - 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5143"/>
                    <measurement group_id="B2" value="5076"/>
                    <measurement group_id="B3" value="5052"/>
                    <measurement group_id="B4" value="5078"/>
                    <measurement group_id="B5" value="20349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65 - 74 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2641"/>
                    <measurement group_id="B2" value="2733"/>
                    <measurement group_id="B3" value="2731"/>
                    <measurement group_id="B4" value="2702"/>
                    <measurement group_id="B5" value="10807"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="551"/>
                    <measurement group_id="B2" value="606"/>
                    <measurement group_id="B3" value="535"/>
                    <measurement group_id="B4" value="561"/>
                    <measurement group_id="B5" value="2253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education (highest)</title>
          <units>Participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;= High school graduate or GED</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1875"/>
                    <measurement group_id="B2" value="1917"/>
                    <measurement group_id="B3" value="1898"/>
                    <measurement group_id="B4" value="1993"/>
                    <measurement group_id="B5" value="7683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some college/vocational school</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2387"/>
                    <measurement group_id="B2" value="2327"/>
                    <measurement group_id="B3" value="2348"/>
                    <measurement group_id="B4" value="2291"/>
                    <measurement group_id="B5" value="9353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= College graduate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4394"/>
                    <measurement group_id="B2" value="4430"/>
                    <measurement group_id="B3" value="4372"/>
                    <measurement group_id="B4" value="4317"/>
                    <measurement group_id="B5" value="17513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown/missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="95"/>
                    <measurement group_id="B5" value="339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PSA (ng/ml)</title>
          <units>Participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0.1 - 1.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4208"/>
                    <measurement group_id="B2" value="4218"/>
                    <measurement group_id="B3" value="4213"/>
                    <measurement group_id="B4" value="4122"/>
                    <measurement group_id="B5" value="16761"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.1 - 2.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2653"/>
                    <measurement group_id="B2" value="2661"/>
                    <measurement group_id="B3" value="2666"/>
                    <measurement group_id="B4" value="2728"/>
                    <measurement group_id="B5" value="10708"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.1 - 3.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1228"/>
                    <measurement group_id="B2" value="1211"/>
                    <measurement group_id="B3" value="1149"/>
                    <measurement group_id="B4" value="1168"/>
                    <measurement group_id="B5" value="4756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.1 - 4.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="634"/>
                    <measurement group_id="B2" value="652"/>
                    <measurement group_id="B3" value="659"/>
                    <measurement group_id="B4" value="666"/>
                    <measurement group_id="B5" value="2611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 4.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown/missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking status</title>
          <units>Participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3752"/>
                    <measurement group_id="B2" value="3780"/>
                    <measurement group_id="B3" value="3666"/>
                    <measurement group_id="B4" value="3682"/>
                    <measurement group_id="B5" value="14880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="659"/>
                    <measurement group_id="B2" value="631"/>
                    <measurement group_id="B3" value="670"/>
                    <measurement group_id="B4" value="655"/>
                    <measurement group_id="B5" value="2615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Former</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4194"/>
                    <measurement group_id="B2" value="4214"/>
                    <measurement group_id="B3" value="4242"/>
                    <measurement group_id="B4" value="4208"/>
                    <measurement group_id="B5" value="16858"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ever (unknown status)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="63"/>
                    <measurement group_id="B5" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="88"/>
                    <measurement group_id="B5" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Prostate Cancer</title>
        <description>Participants are seen at the study site every six month for an update of medical events. Prostate cancer diagnosis is based on participant report followed by the submission of a pathologic sample to central pathology review for confirmation.</description>
        <time_frame>Every six months for 7 to 12 years depending on when the participant was randomized.</time_frame>
        <population>All randomized eligible men not at 2 sites for which the DSMC said the data could not be used due to participant and data management issues as well as regulatory problems.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin E</title>
            <description>Vitamin E + matching placebo for selenium</description>
          </group>
          <group group_id="O2">
            <title>Selenium</title>
            <description>Selenium + matching placebo for vitamin E</description>
          </group>
          <group group_id="O3">
            <title>Combination</title>
            <description>Vitamin E + selenium</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo for vitamin E + matching placebo for selenium</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Prostate Cancer</title>
          <description>Participants are seen at the study site every six month for an update of medical events. Prostate cancer diagnosis is based on participant report followed by the submission of a pathologic sample to central pathology review for confirmation.</description>
          <population>All randomized eligible men not at 2 sites for which the DSMC said the data could not be used due to participant and data management issues as well as regulatory problems.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8737"/>
                <count group_id="O2" value="8752"/>
                <count group_id="O3" value="8703"/>
                <count group_id="O4" value="8696"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="473"/>
                    <measurement group_id="O2" value="432"/>
                    <measurement group_id="O3" value="437"/>
                    <measurement group_id="O4" value="416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Per study design, with a sample size of 32,400 men, using a 1-sided alpha=.005 level (equivalent to a 2-sided alpha=.01 level) there was 96% power to detect a 25% reduction in prostate cancer for either agent vs. Placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; .01</p_value>
            <p_value_desc>The p-value was adjusted for multiple comparisons.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.13</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Per study design, with a sample size of 32,400 men, using a 1-sided alpha=.005 level (equivalent to a 2-sided alpha=.01 level) there was 96% power to detect a 25% reduction in prostate cancer for either agent vs. Placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; .01</p_value>
            <p_value_desc>The p-value was adjusted for multiple comparisons.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Per study design, with a sample size of 32,400 men, using a 1-sided alpha=.005 level (equivalent to a 2-sided alpha=.01 level) there was 99% power to detect a 44% reduction in prostate cancer for combination vs. Placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; .01</p_value>
            <p_value_desc>The p-value was adjusted for multiple comparisons.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>99</ci_percent>
            <ci_lower_limit>.88</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Lung Cancer</title>
        <description>Participants are seen at the study site every six month for an update of medical events. Cancer diagnoses are based on participant report. Medical records for non-prostate cancers were collected but they were not pathologically confirmed. If the participant has been diagnosed with prostate cancer, study site visits are once a year. Follow-up was planned for seven to 12 years depending on when the participant was randomized.</description>
        <time_frame>Participants are assessed for medical every six months for 7 to 12 years depending on when he was randomized . Upon diagnosis of prostate cancer, updates are annual.</time_frame>
        <population>All randomized eligible participants excluding all men from 2 study sites that the DSMC said to exclude due to poor participant/data management and regulatory issues.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin E</title>
            <description>Vitamin E + matching placebo for selenium</description>
          </group>
          <group group_id="O2">
            <title>Selenium</title>
            <description>Selenium + matching placebo for vitamin E</description>
          </group>
          <group group_id="O3">
            <title>Combination</title>
            <description>Vitamin E + selenium</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo for vitamin E + matching placebo for selenium</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Lung Cancer</title>
          <description>Participants are seen at the study site every six month for an update of medical events. Cancer diagnoses are based on participant report. Medical records for non-prostate cancers were collected but they were not pathologically confirmed. If the participant has been diagnosed with prostate cancer, study site visits are once a year. Follow-up was planned for seven to 12 years depending on when the participant was randomized.</description>
          <population>All randomized eligible participants excluding all men from 2 study sites that the DSMC said to exclude due to poor participant/data management and regulatory issues.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8737"/>
                <count group_id="O2" value="8752"/>
                <count group_id="O3" value="8703"/>
                <count group_id="O4" value="8696"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="78"/>
                    <measurement group_id="O4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; .05</p_value>
            <p_value_desc>The trial was designed to study prostate cancer and lung cancer has a lower incidence rate, there was limited power to look at lung cancer incidence. A 99% CI (rather than a 95% CI) was used to adjust for the multiple comparisons.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.0</param_value>
            <ci_percent>99</ci_percent>
            <ci_lower_limit>.64</ci_lower_limit>
            <ci_upper_limit>1.55</ci_upper_limit>
            <estimate_desc>The placebo was the denominator.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; .01</p_value>
            <p_value_desc>The trial was designed to study prostate cancer and lung cancer has a lower incidence rate, there was limited power to look at lung cancer incidence. A 99% CI (rather than a 95% CI) was used to adjust for the multiple comparisons.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.12</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.72</ci_upper_limit>
            <estimate_desc>The placebo was the denominator.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;.01</p_value>
            <p_value_desc>The trial was designed to study prostate cancer and lung cancer has a lower incidence rate, there was limited power to look at lung cancer incidence. A 99% CI (rather than a 95% CI) was used to adjust for the multiple comparisons.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.16</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
            <estimate_desc>The placebo was the denominator.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Colorectal Cancer</title>
        <description>Participants are seen at the study site every six month for an update of medical events. Cancer diagnoses are based on participant report. Medical records for non-prostate cancers were collected but they were not pathologically confirmed. If the participant has been diagnosed with prostate cancer, study site visits are once a year. Follow-up was planned for seven to 12 years depending on when the participant was randomized.</description>
        <time_frame>Participants are assessed for medical every six months for 7 to 12 years depending on when he was randomized . Upon diagnosis of prostate cancer, updates are annual.</time_frame>
        <population>All randomized eligible participants excluding all men from 2 study sites that the DSMC said to exclude due to poor participant/data management and regulatory issues.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin E</title>
            <description>Vitamin E + matching placebo for selenium</description>
          </group>
          <group group_id="O2">
            <title>Selenium</title>
            <description>Selenium + matching placebo for vitamin E</description>
          </group>
          <group group_id="O3">
            <title>Combination</title>
            <description>Vitamin E + selenium</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo for vitamin E + matching placebo for selenium</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Colorectal Cancer</title>
          <description>Participants are seen at the study site every six month for an update of medical events. Cancer diagnoses are based on participant report. Medical records for non-prostate cancers were collected but they were not pathologically confirmed. If the participant has been diagnosed with prostate cancer, study site visits are once a year. Follow-up was planned for seven to 12 years depending on when the participant was randomized.</description>
          <population>All randomized eligible participants excluding all men from 2 study sites that the DSMC said to exclude due to poor participant/data management and regulatory issues.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8737"/>
                <count group_id="O2" value="8752"/>
                <count group_id="O3" value="8703"/>
                <count group_id="O4" value="8696"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The trial was designed to study prostate cancer and colorectal cancer has a lower incidence rate, there was limited power to look at colorectal cancer incidence.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; .05</p_value>
            <p_value_desc>A 99% CI (rather than a 95% CI) was used to adjust for the multiple comparisons.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.73</ci_upper_limit>
            <estimate_desc>The placebo was the denominator.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The trial was designed to study prostate cancer and colorectal cancer has a lower incidence rate, there was limited power to look at colorectal cancer incidence.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; .05</p_value>
            <p_value_desc>A 99% CI (rather than a 95% CI) was used to adjust for the multiple comparisons.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.67</ci_upper_limit>
            <estimate_desc>The placebo was the denominator.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The trial was designed to study prostate cancer and colorectal cancer has a lower incidence rate, there was limited power to look at colorectal cancer incidence.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; .05</p_value>
            <p_value_desc>A 99% CI (rather than a 95% CI) was used to adjust for the multiple comparisons.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.28</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>2.00</ci_upper_limit>
            <estimate_desc>The placebo was the denominator.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Diagnosis of Cancer</title>
        <description>Participants are seen at the study site every six month for an update of medical events. Cancer diagnoses are based on participant report. Medical records for non-prostate cancers were collected but they were not pathologically confirmed. If the participant has been diagnosed with prostate cancer, study site visits are once a year. Follow-up was planned for seven to 12 years depending on when the participant was randomized.</description>
        <time_frame>Participants are assessed for medical every six months for 7 to 12 years depending on when he was randomized . Upon diagnosis of prostate cancer, updates are annual.</time_frame>
        <population>All randomized eligible participants excluding all men from 2 study sites that the DSMC said to exclude due to poor participant/data management and regulatory issues.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin E</title>
            <description>Vitamin E + matching placebo for selenium</description>
          </group>
          <group group_id="O2">
            <title>Selenium</title>
            <description>Selenium + matching placebo for vitamin E</description>
          </group>
          <group group_id="O3">
            <title>Combination</title>
            <description>Vitamin E + selenium</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo for vitamin E + matching placebo for selenium</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Diagnosis of Cancer</title>
          <description>Participants are seen at the study site every six month for an update of medical events. Cancer diagnoses are based on participant report. Medical records for non-prostate cancers were collected but they were not pathologically confirmed. If the participant has been diagnosed with prostate cancer, study site visits are once a year. Follow-up was planned for seven to 12 years depending on when the participant was randomized.</description>
          <population>All randomized eligible participants excluding all men from 2 study sites that the DSMC said to exclude due to poor participant/data management and regulatory issues.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8737"/>
                <count group_id="O2" value="8752"/>
                <count group_id="O3" value="8703"/>
                <count group_id="O4" value="8696"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="856"/>
                    <measurement group_id="O2" value="837"/>
                    <measurement group_id="O3" value="846"/>
                    <measurement group_id="O4" value="824"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The power to look at all cancer incidence is greater than 90%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; .05</p_value>
            <p_value_desc>A 99% CI (rather than a 95% CI) was used to adjust for the multiple comparisons.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
            <estimate_desc>The placebo was the denominator.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The power to look at all cancer incidence is greater than 90%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; .05</p_value>
            <p_value_desc>A 99% CI (rather than a 95% CI) was used to adjust for the multiple comparisons.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
            <estimate_desc>The placebo was the denominator.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The power to look at all cancer incidence is greater than 90%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; .05</p_value>
            <p_value_desc>A 99% CI (rather than a 95% CI) was used to adjust for the multiple comparisons.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>99</ci_percent>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
            <estimate_desc>The placebo was the denominator.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prostate Cancer Free Survival; Lung Cancer-free Survival, Colorectal Cancer-free Survival, Cancer-free Survival, Overall Survival</title>
        <description>Participants are seen at the study site every six month for an update of medical events. If the participant has been diagnosed with prostate cancer, study site visits are once a year. Prostate cancer diagnosis is based on participant report followed by the submission of a pathologic sample to central pathology review for confirmation. Other cancer diagnoses are based on participant report. Medical records for non-prostate cancers were collected but they were not pathologically confirmed. Follow-up was planned for seven to 12 years depending on when the participant was randomized.</description>
        <time_frame>Participants are assessed for medical every six months for 7 to 12 years depending on when he was randomized . Upon diagnosis of prostate cancer, updates are annual.</time_frame>
        <population>All randomized eligible participants excluding all men from 2 study sites that the DSMC said to exclude due to poor participant/data management and regulatory issues. Deaths include those reported as SAEs as well as non-SAE deaths as this was a prevention trial with older generally healthy men at baseline who were followed for a long time.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin E</title>
            <description>Vitamin E + matching placebo for selenium</description>
          </group>
          <group group_id="O2">
            <title>Selenium</title>
            <description>Selenium + matching placebo for vitamin E</description>
          </group>
          <group group_id="O3">
            <title>Combination</title>
            <description>Vitamin E + selenium</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo for vitamin E + matching placebo for selenium</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate Cancer Free Survival; Lung Cancer-free Survival, Colorectal Cancer-free Survival, Cancer-free Survival, Overall Survival</title>
          <description>Participants are seen at the study site every six month for an update of medical events. If the participant has been diagnosed with prostate cancer, study site visits are once a year. Prostate cancer diagnosis is based on participant report followed by the submission of a pathologic sample to central pathology review for confirmation. Other cancer diagnoses are based on participant report. Medical records for non-prostate cancers were collected but they were not pathologically confirmed. Follow-up was planned for seven to 12 years depending on when the participant was randomized.</description>
          <population>All randomized eligible participants excluding all men from 2 study sites that the DSMC said to exclude due to poor participant/data management and regulatory issues. Deaths include those reported as SAEs as well as non-SAE deaths as this was a prevention trial with older generally healthy men at baseline who were followed for a long time.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8737"/>
                <count group_id="O2" value="8752"/>
                <count group_id="O3" value="8703"/>
                <count group_id="O4" value="8696"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="358"/>
                    <measurement group_id="O2" value="378"/>
                    <measurement group_id="O3" value="359"/>
                    <measurement group_id="O4" value="382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All cancer deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="128"/>
                    <measurement group_id="O3" value="117"/>
                    <measurement group_id="O4" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prostate cancer deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung cancer deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colorectal cancer deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Only results from overall survival are presented as the number of cancer-specific deaths is too few to be meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; .05</p_value>
            <p_value_desc>A 99% CI (rather than a 95% CI) was used to adjust for the multiple comparisons.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>99</ci_percent>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
            <estimate_desc>The placebo is the denominator.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Only results from overall survival are presented as the number of cancer-specific deaths is too few to be meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; .05</p_value>
            <p_value_desc>A 99% CI (rather than a 95% CI) was used to adjust for the multiple comparisons.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
            <estimate_desc>The placebo was the denominator.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Only results from overall survival are presented as the number of cancer-specific deaths is too few to be meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; .05</p_value>
            <p_value_desc>A 99% CI (rather than a 95% CI) was used to adjust for the multiple comparisons.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Cardiovascular Events</title>
        <description>Participants are seen at the study site every six month for an update of medical events. If the participant has been diagnosed with prostate cancer, study site visits are once a year. Cardiovascular events are based on self-report and are not confirmed. Follow-up was planned for seven to 12 years depending on when the participant was randomized.</description>
        <time_frame>Participants are assessed for medical every six months for 7 to 12 years depending on when he was randomized . Upon diagnosis of prostate cancer, updates are annual.</time_frame>
        <population>All randomized eligible participants excluding all men from 2 study sites that the DSMC said to exclude due to poor participant/data management and regulatory issues.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin E</title>
            <description>Vitamin E + matching placebo for selenium</description>
          </group>
          <group group_id="O2">
            <title>Selenium</title>
            <description>Selenium + matching placebo for vitamin E</description>
          </group>
          <group group_id="O3">
            <title>Combination</title>
            <description>Vitamin E + selenium</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo for vitamin E + matching placebo for selenium</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Cardiovascular Events</title>
          <description>Participants are seen at the study site every six month for an update of medical events. If the participant has been diagnosed with prostate cancer, study site visits are once a year. Cardiovascular events are based on self-report and are not confirmed. Follow-up was planned for seven to 12 years depending on when the participant was randomized.</description>
          <population>All randomized eligible participants excluding all men from 2 study sites that the DSMC said to exclude due to poor participant/data management and regulatory issues.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8737"/>
                <count group_id="O2" value="8752"/>
                <count group_id="O3" value="8703"/>
                <count group_id="O4" value="8696"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1034"/>
                    <measurement group_id="O2" value="1080"/>
                    <measurement group_id="O3" value="1041"/>
                    <measurement group_id="O4" value="1050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; .05</p_value>
            <p_value_desc>A 99% CI (rather than a 95% CI) was used to adjust for the multiple comparisons.</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
            <estimate_desc>The placebo was the denominator.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; .05</p_value>
            <p_value_desc>A 99% CI (rather than a 95% CI) was used to adjust for the multiple comparisons.</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
            <estimate_desc>The placebo was the denominator.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; .05</p_value>
            <p_value_desc>A 99% CI (rather than a 95% CI) was used to adjust for the multiple comparisons.</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
            <estimate_desc>The placebo was the denominator.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>Study site visits, collected by CRA based on participant interview and annual limited physical exam</desc>
      <group_list>
        <group group_id="E1">
          <title>Selenium Alone</title>
          <description>Selenium + placebo for vitamin E</description>
        </group>
        <group group_id="E2">
          <title>Combination</title>
          <description>Selenium + vitamin E</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo for selenium + placebo for vitamin E</description>
        </group>
        <group group_id="E4">
          <title>Vitamin E Alone</title>
          <description>Vitamin E + placebo for selenium</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="108" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="99" subjects_at_risk="8737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia, NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Cardiovascular-other</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Conduction abnormality/block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>LVEF decrease/CHF</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Supraventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="8737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye-other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Vision,NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia/heartburn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>GI-other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Melena/ GI bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Rectal bleeding/hematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional symptoms-other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Hemorrhage w/o 3-4 thrombocyt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Pain-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Reportable adverse event, NOS</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="8737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver-clinical</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Liver-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Respiratory infect w/o neutrop</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Respiratory infection, unk ANC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Urinary tr infect w/o neutrop</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Surgery-hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Myalgia/arthralgia, NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Second primary</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="8737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Cerebrovascular ischemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Cranial neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Neuro-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Seizures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile impotence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ARDS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Emphysema/COPD</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Carotid stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Peripheral arterial ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="8737"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2605" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="2550" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="2421" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="2553" subjects_at_risk="8737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" subjects_affected="558" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="533" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="529" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="551" subjects_at_risk="8737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Halitosis</sub_title>
                <counts group_id="E1" subjects_affected="523" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="555" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="447" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="517" subjects_at_risk="8737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue/malaise/lethargy</sub_title>
                <counts group_id="E1" subjects_affected="698" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="657" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="632" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="660" subjects_at_risk="8737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="647" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="593" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="554" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="627" subjects_at_risk="8737"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" subjects_affected="1129" subjects_at_risk="8752"/>
                <counts group_id="E2" subjects_affected="1080" subjects_at_risk="8702"/>
                <counts group_id="E3" subjects_affected="1072" subjects_at_risk="8696"/>
                <counts group_id="E4" subjects_affected="1070" subjects_at_risk="8737"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Statistician</name_or_title>
      <organization>SWOG Statistical Center</organization>
      <phone>2066674623</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

